Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
Weien Yuan, Xinxin Yang, Ruiyuan Zheng, et al.
International Journal of Nanomedicine (2012), pp. 2077-2077
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Akhand Pratap Singh, Arpan Biswas, Aparna Wagle Shukla, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 511
Trans-Blood Brain Barrier Delivery of Dopamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Rats
Richa Pahuja, Kavita Seth, Anshi Shukla, et al.
ACS Nano (2015) Vol. 9, Iss. 5, pp. 4850-4871
Open Access | Times Cited: 227
Multifunctional nanoparticle-mediated combining therapy for human diseases
Xiaotong Li, Xiuju Peng, Makhloufi Zoulikha, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 125
Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
Virendra Kumar Yadav, Seshathiri Dhanasekaran, Nisha Choudhary, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 2
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases
Howard E. Gendelman, Vellareddy Anantharam, Tatiana K. Bronich, et al.
Nanomedicine Nanotechnology Biology and Medicine (2015) Vol. 11, Iss. 3, pp. 751-767
Open Access | Times Cited: 111
Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases
Sibel Bozdağ Pehlivan
Pharmaceutical Research (2013) Vol. 30, Iss. 10, pp. 2499-2511
Closed Access | Times Cited: 103
Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain
Gerardo Leyva‐Gómez, Hernán Cortés, Jonathan J. Magaña, et al.
Drug Discovery Today (2015) Vol. 20, Iss. 7, pp. 824-837
Closed Access | Times Cited: 97
Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach
Matteo Bordoni, Eveljn Scarian, Federica Rey, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3243-3243
Open Access | Times Cited: 80
Levodopa-loaded nanoparticles for the treatment of Parkinson's disease
Emile F. van Vliet, Maarten J. Knol, Raymond M. Schiffelers, et al.
Journal of Controlled Release (2023) Vol. 360, pp. 212-224
Open Access | Times Cited: 29
Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems
Elisa Garbayo, Eduardo Ansorena, María J. Blanco‐Prieto
Maturitas (2013) Vol. 76, Iss. 3, pp. 272-278
Open Access | Times Cited: 79
In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery
Sema Arısoy, Özgün SAYINER, Tansel Çomoğlu, et al.
Pharmaceutical Development and Technology (2020) Vol. 25, Iss. 6, pp. 735-747
Closed Access | Times Cited: 66
Nanoparticles in Combating Neuronal Dysregulated Signaling Pathways: Recent Approaches to the Nanoformulations of Phytochemicals and Synthetic Drugs Against Neurodegenerative Diseases
Sajad Fakhri, Sadaf Abdian, Seyede Nazanin Zarneshan, et al.
International Journal of Nanomedicine (2022) Vol. Volume 17, pp. 299-331
Open Access | Times Cited: 31
Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease
Sara Hernando, Edorta Santos‐Vizcaíno, Manoli Igartúa, et al.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2023) Vol. 15, Iss. 5
Open Access | Times Cited: 17
Nanobiomaterials’ applications in neurodegenerative diseases
Daniela Silva‐Adaya, Lucinda Aguirre‐Cruz, Jorge Guevara, et al.
Journal of Biomaterials Applications (2016) Vol. 31, Iss. 7, pp. 953-984
Closed Access | Times Cited: 54
Nanoparticles for drug delivery in Parkinson’s disease
Jonathan Baskin, June Jeon, Simon J.G. Lewis
Journal of Neurology (2020) Vol. 268, Iss. 5, pp. 1981-1994
Closed Access | Times Cited: 45
Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease
Obaydah Abd Alkader Alabrahim, Hassan Mohamed El-Said Azzazy
Nanoscale Advances (2022) Vol. 4, Iss. 24, pp. 5233-5244
Open Access | Times Cited: 24
The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems
Deepa D. Nakmode, Candace M. Day, Yunmei Song, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1503-1503
Open Access | Times Cited: 15
Designing and Formulation of Nanocarriers for “Alzheimer’s and Parkinson’s” Early Detection and Therapy
Jakleen Abujamai, Rukhsana Satar, Shakeel Ahmed Ansari
CNS & Neurological Disorders - Drug Targets (2024) Vol. 23, Iss. 10, pp. 1251-1262
Closed Access | Times Cited: 5
Parkinson's disease: Current drug therapy and unraveling the prospects of nanoparticles
Ankita Paul, Khushwant S. Yadav
Journal of Drug Delivery Science and Technology (2020) Vol. 58, pp. 101790-101790
Closed Access | Times Cited: 35
Nanotheranostics revolutionizing neurodegenerative diseases: From precision diagnosis to targeted therapies
Riya Joshi, Hemi Missong, Jayapriya Mishra, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 89, pp. 105067-105067
Closed Access | Times Cited: 11
Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds
Jiani Lu, Yan Tang, Hongtao Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2243-2243
Open Access
Advances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases
Sara Hernando, Oihane Gartziandia, Enara Herrán, et al.
Nanomedicine (2016) Vol. 11, Iss. 10, pp. 1267-1285
Closed Access | Times Cited: 38
Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Elisa Garbayo, Ander Estella‐Hermoso de Mendoza, María J. Blanco‐Prieto
Current Medicinal Chemistry (2014) Vol. 21, Iss. 36, pp. 4100-4131
Open Access | Times Cited: 35
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats
Cheng-long Xie, Wenwen Wang, Sufang Zhang, et al.
Scientific Reports (2014) Vol. 4, Iss. 1
Open Access | Times Cited: 30
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats
Chenglong Xie, Jingya Lin, Meihua Wang, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top